Clinical Efficacy and Safety of Pinggan Huoxue Acupoint Application for Grade 1 Hypertension: A Randomized, Double-blind, Placebo-controlled, Multicenter Trial

Evaluation of the Comprehensive Efficacy of Pinggan Huoxue Acupoint Application on Grade 1 Hypertension

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063910

Enrollment

Unknown

Registered

2022-09-20

Start date

2022-09-20

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Pinggan Huoxue acupoint application group:Pinggan Huoxue acupoint application + lifestyle intervention

Pinggan Huoxue acupoint application placebo group:Pinggan Huoxue acupoint application placebo + lifestyle intervention

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The subjects meet the Western medicine diagnostic criteria for Grade 1 hypertension; 2. The subjects met the diagnostic criteria of liver-yang hyperactivity and blood stasis blocking collaterals; 3. Aged 18-65 years; 4. No medication (Western medicine, Chinese medicine) or acupuncture therapy to control blood pressure (or have stopped treatment for 2 weeks); 5. Agree to be randomly assigned to Pinggan Huoxue Patch group or life intervention group; 6. Volunteer to participate in the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary hypertension; 2. Target organ damage caused by cardiovascular disease, chronic kidney disease, diabetes or hypertension; 3. Pregnant and lactating patients; 4. Benzodiazepines, antipsychotics or oral glucocorticoids (fluoxetine, paroxetine, Sertraline, fluvoxamine, citalopram and escitalopram are allowed for stable use for three months); 5. Complicated with severe liver and kidney diseases and cerebrovascular accidents; 6. Known autonomic neuropathy (e.g. Shy-Drager syndrome, orthostatic hypotension, white coat hypertension); 7. Male alcohol intake >=25g/ day (about 65ml Beijing Erguotou), or >=140g/ week; Female alcohol intake >=15g/ day (about 33ml Beijing Erguotou), or >=80g/ week; 8. Currently participating in clinical trials of other drugs or external treatment; 9. Easy to produce skin allergies to drugs and dressings.

Design outcomes

Primary

Measure	Time frame
Blood pressure;Ambulatory blood pressure;	—

Secondary

Measure	Time frame
Traditional Chinese medicine syndrome;SF-36 Quality of life;	—

Countries

China

Contacts

Public ContactHe Qingyong

Guang 'anmen Hospital, China Academy of Chinese Medical Sciences

heqingyongg@163.com+86 13581965248

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026